#regulation

Cal Newport argues that OpenAI's and Anthropic's recent public messaging - rogue-agent warnings, employee debates over extinction risk, and Dario Amodei's 'pace the frontier' letter - reads less as transparency than as a campaign to cast the labs as humanity's reluctant saviors. He calls for a congressional fact-finding effort into what research the labs are actually running, their internal safety procedures, and the apocalyptic ideologies shaping those decisions.

Anthropic CEO Dario Amodei argues that recursive self-improvement and the OpenAI/Hugging Face hacking incident mean AI companies now need to deliberately slow the pace of capability gains so that alignment, interpretability, and safety testing can keep up. He proposes a three-step 'pacing the frontier' plan: embedded third-party evaluators (which Anthropic is unilaterally adopting), industry-wide democratic coordination on safety standards, and eventual global coordination with authoritarian governments.

The SEC's proposal to let companies report financials twice a year instead of quarterly drew a record ~221,000 public comments, with more than 99% opposed — individual investors, institutional investors, former SEC officials, and academics all argued that quarterly 10-Qs are essential to how they price and track companies.

Epidemiologist Katelyn Jetelina breaks down BPC-157, TB-500, and the peptide boom — what the science actually shows (mostly animal studies), the regulatory whiplash after RFK Jr.'s Rogan appearance, and why people skeptical of vaccines embrace compounds with even less human evidence.

The asymmetry framing is sharp — the same post hoc fallacy that drives vaccine skepticism ("got the shot, then got sick") gets applied in reverse for peptides ("injected it, tendon healed"), but without the control group skepticism. Worth noting: RFK Jr.'s Rogan announcement in February 2026 changed no FDA rules — as of publication, compounding peptides like BPC-157 remained legally restricted.